India is at the epicentre of the global antimicrobial resistance (AMR) crisis. According to the World Health Organization, drug-resistant infections kill at least 1.27 million people worldwide each year — and India accounts for a disproportionate share of that burden. The ICMR AMR Surveillance Network, which monitors resistance patterns across hospitals in multiple Indian states, has documented alarming rates of resistance to carbapenems, cephalosporins, and fluoroquinolones — antibiotics that form the backbone of treatment for life-threatening infections.

A significant driver of this crisis is irrational prescribing: antibiotics prescribed without adequate clinical indication, for viral infections that do not respond to them, at incorrect doses or durations, or chosen from the broadest spectrum available when a narrower antibiotic would suffice. The medico-legal question that is beginning to gain traction in India is this: can a doctor be held legally liable for irrational antibiotic prescribing?

The answer is more nuanced — and more serious for the prescribing physician — than most doctors currently appreciate.

"The law has not yet imposed direct liability for antibiotic resistance in India, but the regulatory and civil pathways are opening. A doctor who prescribes a broad-spectrum antibiotic without documenting clinical justification is taking a risk that grows every year."
— Dr. Namit Gupta, Senior Medico-Legal Expert

India's AMR Crisis: The Scale of the Problem

India consumes more antibiotics than any other country in the world in absolute terms. The ICMR's annual AMR reports have consistently shown that major pathogens — including Klebsiella pneumoniae, Acinetobacter baumannii, E. coli, and Pseudomonas aeruginosa — show extremely high resistance rates to commonly prescribed antibiotics in Indian hospital settings.

The National Action Plan on AMR 2017–2021 — India's response to the WHO's Global Action Plan — identified irrational antibiotic use in human health, agriculture, and food production as primary drivers of resistance. The NAP on AMR called for strengthening prescription practices, establishing antibiotic stewardship programmes in hospitals, and improving public awareness about antibiotic use. A successor plan extending these commitments was developed for the 2022–2026 period.

Despite these policy frameworks, over-the-counter antibiotic sales — technically illegal under Schedule H and H1 of the Drugs and Cosmetics Rules — remain widespread. And within the formal healthcare system, prescribing broad-spectrum antibiotics as a first-line response remains common practice.

What Does "Irrational Prescribing" Mean Legally?

There is no single statutory definition of "irrational prescribing" in Indian law, but the concept is embedded in several regulatory frameworks. A prescription may be considered irrational if:

  • An antibiotic is prescribed for a condition that is almost certainly viral in origin (such as the common cold, influenza, or uncomplicated acute bronchitis in an otherwise healthy adult), where no antibiotic has clinical benefit
  • A broad-spectrum or last-resort antibiotic is prescribed when a narrower-spectrum drug would be clinically equivalent
  • No culture and sensitivity (C&S) testing was ordered before prescribing a broad-spectrum antibiotic, in a clinical situation where infection with a resistant organism was reasonably foreseeable
  • The antibiotic is prescribed at an incorrect dose or for an inappropriate duration
  • The prescription is made without examining the patient or without documented clinical reasoning

Against this backdrop, the legal standard — the Bolam test as applied in India — asks: would a reasonably competent doctor of the same specialty, given the same clinical information, have prescribed in the same way? Where the answer is clearly no — for example, a doctor who prescribes a carbapenem for a routine urinary tract infection without any documented indication — the prescribing may fall below the legal standard of care.

Schedule H1: The Regulatory Framework for Critical Antibiotics

The most direct legal mechanism governing antibiotic prescribing in India is Schedule H1, introduced by the Drugs and Cosmetics (Amendment) Rules, 2013. Schedule H1 was specifically created to regulate a class of antibiotics identified as critical to human medicine — including third-generation and later cephalosporins, carbapenems, fluoroquinolones, and certain antifungals and antivirals.

Under Schedule H1:

  • These drugs can only be dispensed by a pharmacist against a written prescription from a Registered Medical Practitioner
  • The pharmacist must maintain a separate prescription register recording each dispensing, to be retained for two years
  • The prescription cannot be dispensed a second time without a fresh prescription from the doctor
  • The package must carry a prominent red strip and the label "Schedule H1 Drug — Warning: To be sold by retail on the prescription of a Registered Medical Practitioner only"

The purpose of Schedule H1 is unambiguously linked to AMR prevention. A doctor who prescribes a Schedule H1 antibiotic without documented clinical justification — and a pharmacist who dispenses it without a valid prescription — may face action under the Drugs and Cosmetics Act, 1940. More significantly from a medico-legal perspective, the very existence of Schedule H1 establishes a regulatory standard: these antibiotics require documented, reasoned clinical justification.

The Consumer Forum Angle: Can a Patient Claim Compensation?

Under the Consumer Protection Act, 2019, a medical consultation is a "service" and deficiency in that service — including negligent prescribing — can give rise to a complaint before the District, State, or National Consumer Disputes Redressal Commission.

The Causation Challenge

The most significant legal challenge in an antibiotic resistance case is causation. A patient who develops a drug-resistant infection after receiving an antibiotic must establish not only that the prescribing was irrational but that it was this irrational prescribing — rather than pre-existing resistance, hospital-acquired infection, or other factors — that caused the resistant infection and the resulting harm.

This is a genuinely difficult causal chain to establish, and it explains why direct litigation for antibiotic resistance remains rare in India. However, a more tractable scenario exists: a patient who suffers harm directly from the antibiotic itself — an adverse drug reaction, C. difficile colitis from broad-spectrum antibiotic use, or a severe allergic reaction — may have a more straightforward claim if the antibiotic was prescribed without adequate clinical indication and without taking an adequate medication history.

A Case Study Scenario

Consider this scenario: A 45-year-old patient presents to a private clinic with a mild upper respiratory tract infection. The doctor, without examining the patient properly, prescribes a combination of a fluoroquinolone and a cephalosporin — both Schedule H1 drugs — without documenting any clinical reasoning and without asking about prior antibiotic use or allergies. Three weeks later, the patient develops severe C. difficile-associated diarrhoea requiring hospitalisation. Microbiology testing confirms the association with the prior broad-spectrum antibiotic use.

In this scenario, the patient has a viable consumer forum complaint: the prescribing was irrational (broad-spectrum antibiotics for a viral URTI), it fell below the Bolam standard, and the harm — C. difficile colitis — is a well-recognised complication of unnecessary broad-spectrum antibiotic use with a direct causal link to the prescribing decision.

NMC Professional Misconduct: The Regulatory Pathway

The National Medical Commission Regulations 2023 — which govern the ethical conduct of registered medical practitioners — impose a duty on doctors to prescribe rationally. The NMC Code of Medical Ethics requires doctors to prescribe in accordance with standard treatment guidelines, to avoid unnecessary investigations and treatments, and to act in the patient's best interest rather than for financial or commercial considerations.

A complaint to the State Medical Council (and on appeal, the NMC Ethics and Medical Registration Board) alleging that a doctor prescribed antibiotics irrationally — particularly where evidence exists of a pattern of practice rather than a single incident — is legally maintainable. While such complaints have historically been difficult to prosecute, the regulatory framework supports them, and as AMR consciousness grows within the medical establishment, enforcement may follow.

Doctors who receive prescribing-related incentives from pharmaceutical companies — in violation of the MCI/NMC prohibition on gifts and benefits — face a compounded risk, as this could transform an irrational prescribing allegation into a more serious professional misconduct case.

WHO Essential Medicines and ICMR Treatment Guidelines

The WHO's AWaRe classification (Access, Watch, Reserve) provides a global framework for antibiotic stewardship. Access antibiotics are first-choice agents for common infections. Watch antibiotics (including many fluoroquinolones and third-generation cephalosporins) should be used only when first-line agents fail or when the clinical picture specifically warrants them. Reserve antibiotics (including carbapenems and polymyxins) should be used only as a last resort for confirmed MDR infections.

ICMR publishes treatment guidelines for common infections that align with the AWaRe framework and represent the most current evidence-based prescribing standards in India. A court or consumer forum considering whether a prescribing decision met the standard of care would logically look to these guidelines. A doctor who can demonstrate that their prescribing was consistent with ICMR guidelines — or who documented a specific clinical reason to depart from them — is in a far stronger legal position than one who cannot.

Antibiotic Stewardship Committees: NABH Requirements

For hospitals seeking NABH (National Accreditation Board for Hospitals) accreditation, Antibiotic Stewardship Committees are a requirement. These committees are responsible for:

  • Developing and maintaining a hospital antibiotic formulary
  • Creating and updating empiric antibiotic prescribing guidelines based on local resistance data
  • Monitoring antibiotic prescribing patterns across departments
  • Reviewing cases of broad-spectrum antibiotic use and prolonged antibiotic courses
  • Generating regular reports on antibiotic consumption and resistance trends

A hospital that fails to maintain an Antibiotic Stewardship Committee — or has one only on paper — faces accreditation risk. More importantly, in a negligence claim against the hospital, the absence of stewardship structures can be cited as evidence of systemic failure to meet the standard of care in infection management.

How Doctors Can Protect Themselves

The medico-legal risk attached to antibiotic prescribing is real and growing. Doctors can take concrete steps to protect themselves:

1. Culture Sensitivity Testing Before Broad-Spectrum Antibiotics

Where clinically appropriate — in hospitalised patients, in patients with recurrent or treatment-failing infections, and in infections where resistant organisms are plausible — obtain cultures before starting empiric broad-spectrum therapy. Document clearly in the notes why empiric therapy was started before results were available, and review and de-escalate when results return.

2. Document Clinical Reasoning

Every prescription for a Schedule H1 antibiotic should be accompanied by documented clinical reasoning in the patient's record: the diagnosis, the clinical signs supporting it, why this antibiotic was chosen, the duration prescribed, and any counselling given. This documentation is the primary legal protection for the prescribing doctor.

3. Follow ICMR and WHO Guidelines

Prescribing that follows ICMR treatment guidelines or WHO AWaRe recommendations is presumptively reasonable. Where you depart from guidelines, document why — specific patient factors, local resistance data, allergy history, prior treatment failure.

4. Record Allergy and Resistance History

Take and record a full medication history including prior antibiotic use, any previous culture results showing resistance, and known drug allergies. Prescribing an antibiotic to which a patient has a documented allergy, or choosing an antibiotic to which the patient's documented organism is resistant, is very difficult to defend.

5. Comply with Schedule H1 Documentation Requirements

Ensure that prescriptions for Schedule H1 antibiotics are written clearly with your registration number, the diagnosis, and the dosage, as required under the Drugs and Cosmetics Rules. A proper prescription demonstrates the formality and seriousness with which the prescribing decision was made.

Conclusion: A Growing Legal Risk

Antibiotic resistance is not yet routinely litigated as a cause of action in Indian courts. But the regulatory infrastructure — Schedule H1, NABH stewardship requirements, NMC ethical obligations, and the consumer forum framework — already provides the tools for such claims. As public awareness of AMR grows and India's legal profession becomes more familiar with the science, the medico-legal exposure of doctors who prescribe irrationally will only increase.

The prudent approach is not to wait for the law to catch up. Documenting clinical reasoning, following evidence-based guidelines, and treating every Schedule H1 antibiotic prescription as a decision that may one day be scrutinised by a court is not only good legal protection — it is good medicine.

If you are facing questions about your prescribing practices before the NMC, a State Medical Council, or a consumer forum, contact our medico-legal team for expert advice and representation.